Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 90 versus RENOVUE DIP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 90 versus RENOVUE DIP.
HYPAQUE-M,90% vs RENOVUE-DIP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ionic, high-osmolality iodinated contrast agent that absorbs X-rays, enhancing radiographic contrast by attenuating X-rays in tissues where it distributes.
RENOVUE-DIP is a radiocontrast agent, not a drug with pharmacological activity. It is a diagnostic agent that contains diatrizoate meglumine and diatrizoate sodium, which are ionic iodinated compounds. They work by attenuating X-rays, providing contrast in imaging studies. The mechanism is physical rather than pharmacological, increasing the radiodensity of vascular structures and tissues.
Intra-arterial or intravenous injection: 30-60 mL of 90% solution, administered as a bolus or infusion over 1-2 minutes; repeat dosing not recommended.
5 mg orally once daily for hypertension; 2.5 mg orally once daily for diabetic nephropathy.
None Documented
None Documented
Terminal half-life: 1-2 hours (normal renal function); prolonged in renal impairment
Terminal half-life: 2.5 hours (range 2–3 hours); clinically, dosing interval is every 4 hours due to slow redistribution from effect site.
Renal: >95% unchanged; biliary/fecal: <5%
Renal: 95% (60% unchanged, 35% as major metabolite); Biliary/Fecal: 5% as conjugates.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent